Find Sparsentan manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 254740-64-2, Sparsentan (re-021), Re-021, Sparsentan [usan], Ps433540, Ps-433540
Molecular Formula
C32H40N4O5S
Molecular Weight
592.8  g/mol
InChI Key
WRFHGDPIDHPWIQ-UHFFFAOYSA-N
FDA UNII
9242RO5URM

Sparsentan
Sparsentan has been used in trials studying the treatment of Focal Segmental Glomerulosclerosis. Sparsentan is the first and only dual-acting angiotensin and endothelin receptor antagonist (DARA) in development.
1 2D Structure

Sparsentan

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
2.1.2 InChI
InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
2.1.3 InChI Key
WRFHGDPIDHPWIQ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC
2.2 Other Identifiers
2.2.1 UNII
9242RO5URM
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-

2. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide

3. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide

4. Re-021

2.3.2 Depositor-Supplied Synonyms

1. 254740-64-2

2. Sparsentan (re-021)

3. Re-021

4. Sparsentan [usan]

5. Ps433540

6. Ps-433540

7. 9242ro5urm

8. Chembl539423

9. 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide

10. 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-n-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide

11. Retrophin

12. (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-

13. [1,1'-biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-

14. Unii-9242ro5urm

15. Dara

16. Compound 7 [pmid 15634011]

17. Dara-a

18. Ps 33540

19. Sparsentan [inn]

20. Sparsentan (usan/inn)

21. Sparsentan(ps433540)

22. Sparsentan [who-dd]

23. Schembl535109

24. Gtpl8448

25. Amy38147

26. Bcp23969

27. Ex-a3048

28. Bdbm50175523

29. S6665

30. Cs-7947

31. Db12548

32. Sb16876

33. Dara-a (dual Acting Receptor Antagonist Of Angiotension And Endothelin Receptors)

34. Ps-433540;re-021;dara

35. Ac-35179

36. Hy-17621

37. Sparsentan (ps-433540,re-021,dara)

38. D11776

39. F77045

40. A858308

41. L023324

42. Q27088845

43. 4''''-(2-butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''''-ethoxymethyl-biphenyl-2-sulfonic Acid (4,5-dimethyl-isoxazol-3-yl)-amide

44. 4''-(2-butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''-ethoxymethyl-biphenyl-2-sulfonic Acid (4,5-dimethyl-isoxazol-3-yl)-amide

45. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyi)-n-(4,5- Dimethylisoxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide

46. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide

47. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 592.8 g/mol
Molecular Formula C32H40N4O5S
XLogP35
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count12
Exact Mass592.27194156 g/mol
Monoisotopic Mass592.27194156 g/mol
Topological Polar Surface Area123 Ų
Heavy Atom Count42
Formal Charge0
Complexity1060
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of focal segmental glomerulosclerosis


Treatment of primary IgA nephropathy


5 Pharmacology and Biochemistry
5.1 Mechanism of Action

Sparsentan, which possesses two clinically validated mechanisms of action in a single molecule, works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Sparsentan is highly selective (10,000-fold) for the AII receptor sub-type 1 and the ET receptor sub-type A. As such, Sparsentan combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule.


API SUPPLIERS

read-more
read-more

01

Seqens

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Flag France
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Seqens Company Banner

02

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Delivering Trusted, High-Quality APIs to 35+ Countries with Innovation, Compliance, and Excellence.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

03

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

04

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

05

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AGGSpend
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AGGSpend
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

Beijing Sjar Technology Developmen...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AGGSpend
Not Confirmed
arrow

07

Conscientia Industrial

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AGGSpend
Not Confirmed
arrow

08

Excenen PharmaTech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AGGSpend
Not Confirmed
arrow

Excenen PharmaTech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AGGSpend
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

FandaChem

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AGGSpend
Not Confirmed
arrow

FandaChem

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AGGSpend
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Gyma Laboratories of America

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AGGSpend
Not Confirmed
arrow
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

SPARSENTAN

NDC Package Code : 72640-038

Start Marketing Date : 2025-03-29

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Shanghai SynTheAll Pharmaceutical C...

Country
AGGSpend
Not Confirmed
arrow

Shanghai SynTheAll Pharmaceutical C...

Country
arrow
AGGSpend
Not Confirmed

SPARSENTAN

NDC Package Code : 24538-021

Start Marketing Date : 2023-02-17

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is indicated for the treatment of focal segmental glomerulosclerosis.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: Filspari

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 15, 2025

blank

01

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is indicated for the treatment of focal segmental glomerulosclerosis.

Product Name : Filspari

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 15, 2025

blank

Details:

Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: Filspari

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: CSL Vifor

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 29, 2025

blank

02

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.

Product Name : Filspari

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

April 29, 2025

blank

Details:

Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of focal segmental glomerulosclerosis.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: Filspari

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 17, 2025

blank

03

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of focal segmental glomerulosclerosis.

Product Name : Filspari

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 17, 2025

blank

Details:

Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of focal segmental glomerulosclerosis.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: Filspari

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 11, 2025

blank

04

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of focal segmental glomerulosclerosis.

Product Name : Filspari

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 11, 2025

blank

Details:

RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: RE-021

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 30, 2025

blank

05

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.

Product Name : RE-021

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 30, 2025

blank

Details:

The company intends to use the net proceeds for commercialization expenses of its products including Filspari (sparsentan) used for the treatment of adults with primary immunoglobulin A nephropathy.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: Filspari

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Jefferies

Deal Size: $143.8 million Upfront Cash: Undisclosed

Deal Type: Public Offering December 11, 2024

blank

06

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : The company intends to use the net proceeds for commercialization expenses of its products including Filspari (sparsentan) used for the treatment of adults with primary immunoglobulin A nephropathy.

Product Name : Filspari

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 11, 2024

blank

Details:

Filspari (sparsentan) is an oral medication targeting endothelin-1 and angiotensin II pathways in IgAN, approved for treating IgA nephropathy.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: Filspari

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 03, 2024

blank

07

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Filspari (sparsentan) is an oral medication targeting endothelin-1 and angiotensin II pathways in IgAN, approved for treating IgA nephropathy.

Product Name : Filspari

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 03, 2024

blank

Details:

Filspari (sparsentan) is a once-daily approved oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II).


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: Filspari

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Vifor Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 17, 2024

blank

08

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : Filspari (sparsentan) is a once-daily approved oral medication, designed to selectively target two critical pathways in the disease progression of IgAN (endothelin-1 and angiotensin II).

Product Name : Filspari

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 17, 2024

blank

Details:

RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: RE-021

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 18, 2024

blank

09

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : RE-021 (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.

Product Name : RE-021

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 18, 2024

blank

Details:

The financing will enable Renalys Pharma to complete its Phase III clinical trial for RE-021 (sparsentan), a promising treatment for IgA nephropathy, in Japan.


Lead Product(s): Sparsentan

Therapeutic Area: Nephrology Brand Name: RE-021

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Catalys Pacific

Deal Size: $38.8 million Upfront Cash: Undisclosed

Deal Type: Series A Financing July 17, 2024

blank

10

AGGSpend
Not Confirmed
AGGSpend
Not Confirmed

Details : The financing will enable Renalys Pharma to complete its Phase III clinical trial for RE-021 (sparsentan), a promising treatment for IgA nephropathy, in Japan.

Product Name : RE-021

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

July 17, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

SPARSENTAN

Brand Name : FILSPARI

Dosage Form : TABLET;ORAL

Dosage Strength : 200MG

Packaging :

Approval Date : 2023-02-17

Application Number : 216403

Regulatory Info : RX

Registration Country : USA

blank

02

AGGSpend
Not Confirmed
arrow
arrow
AGGSpend
Not Confirmed

SPARSENTAN

Brand Name : FILSPARI

Dosage Form : TABLET;ORAL

Dosage Strength : 400MG

Packaging :

Approval Date : 2023-02-17

Application Number : 216403

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions
The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.

Impressions: 1751

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions

#PharmaFlow by PHARMACOMPASS
15 May 2025

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 254740-64-2 / Sparsentan API manufacturers, exporters & distributors?

Sparsentan manufacturers, exporters & distributors 1

36

PharmaCompass offers a list of Sparsentan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sparsentan manufacturer or Sparsentan supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sparsentan manufacturer or Sparsentan supplier.

PharmaCompass also assists you with knowing the Sparsentan API Price utilized in the formulation of products. Sparsentan API Price is not always fixed or binding as the Sparsentan Price is obtained through a variety of data sources. The Sparsentan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Sparsentan

Synonyms

254740-64-2, Sparsentan (re-021), Re-021, Sparsentan [usan], Ps433540, Ps-433540

Cas Number

254740-64-2

Unique Ingredient Identifier (UNII)

9242RO5URM

About Sparsentan

Sparsentan has been used in trials studying the treatment of Focal Segmental Glomerulosclerosis. Sparsentan is the first and only dual-acting angiotensin and endothelin receptor antagonist (DARA) in development.

Sparsentan Manufacturers

A Sparsentan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sparsentan, including repackagers and relabelers. The FDA regulates Sparsentan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sparsentan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Sparsentan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Sparsentan Suppliers

A Sparsentan supplier is an individual or a company that provides Sparsentan active pharmaceutical ingredient (API) or Sparsentan finished formulations upon request. The Sparsentan suppliers may include Sparsentan API manufacturers, exporters, distributors and traders.

click here to find a list of Sparsentan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Sparsentan USDMF

A Sparsentan DMF (Drug Master File) is a document detailing the whole manufacturing process of Sparsentan active pharmaceutical ingredient (API) in detail. Different forms of Sparsentan DMFs exist exist since differing nations have different regulations, such as Sparsentan USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Sparsentan DMF submitted to regulatory agencies in the US is known as a USDMF. Sparsentan USDMF includes data on Sparsentan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sparsentan USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Sparsentan suppliers with USDMF on PharmaCompass.

Sparsentan NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sparsentan as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Sparsentan API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Sparsentan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Sparsentan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sparsentan NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Sparsentan suppliers with NDC on PharmaCompass.

Sparsentan GMP

Sparsentan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Sparsentan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sparsentan GMP manufacturer or Sparsentan GMP API supplier for your needs.

Sparsentan CoA

A Sparsentan CoA (Certificate of Analysis) is a formal document that attests to Sparsentan's compliance with Sparsentan specifications and serves as a tool for batch-level quality control.

Sparsentan CoA mostly includes findings from lab analyses of a specific batch. For each Sparsentan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Sparsentan may be tested according to a variety of international standards, such as European Pharmacopoeia (Sparsentan EP), Sparsentan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sparsentan USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty